Home › Funds › Citadel Advisors › BCLI
Citadel Advisors position in BCLI
BRAINSTORM CELL THERAPEUTICS
Latest position (Q3 2024)40.40K sh
Reported value held$9.30K
Portfolio Weight0.00%
First reportedQ3 2021
Last changeReduce
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2021 | 220.28K | $727.00K | New |
| Q4 2021 | 203.00K | $812.00K | Reduce |
| Q1 2022 | 119.12K | $400.00K | Reduce |
| Q2 2022 | 139.38K | $384.00K | Add |
| Q3 2022 | 158.21K | $699.00K | Add |
| Q4 2022 | 178.16K | $292.19K | Add |
| Q1 2023 | 201.17K | $663.85K | Add |
| Q2 2023 | 196.16K | $404.08K | Reduce |
| Q3 2023 | 209.50K | $41.92K | Add |
| Q4 2023 | 76.60K | $20.91K | Reduce |
| Q1 2024 | 51.20K | $28.91K | Reduce |
| Q2 2024 | 47.20K | $15.98K | Reduce |
| Q3 2024 | 40.40K | $9.30K | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.